Trial Profile
An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Elderly and Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Aug 2014
Price :
$35
*
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 24 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 07 May 2014 New trial record